Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

60 results about "Cystein protease" patented technology

Cysteine protease is an enzyme that breaks down chains of amino acids that make up protein known as polypeptides. A cysteine protease inhibitor is a substance that targets this enzyme. Pathogens are shown to use cysteine proteases in their mechanisms of action.

Compositions relating to a mutant clostridium difficile toxin and methods thereof

In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and / or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
Owner:WYETH LLC

Inducible self-cleaving protease tag and method of purifying recombinant proteins using the same

A method of purifying a protein is disclosed which entails: a) fusing a site-specific affinity-tagged cysteine protease domain to a target protein to form a tagged fusion protein; b) activating the site-specific cysteine protease domain of the tagged fusion protein by subjecting the site-specific affinity-tagged cysteine protease domain to an inducer, which induces autoprocessing at a cleavage site; thereby releasing untagged target protein; and c) isolating the untagged target protein.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Peptidyl allyl sulfones

The present disclosure provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure include peptidyl allyl sulfone compositions that inhibit proteases, for example cysteine proteases, either in vivo or in vitro.
Owner:GEORGIA TECH RES CORP

Carboxamide compounds and their use as calpain inhibitors

InactiveUS20100216844A1High selectivitySufficient cytosolic stabilityAntibacterial agentsBiocideDiseaseCysteine thiolate
The present invention relates to novel carboxamide compounds and their use as a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity and to a method for the therapeutic and / or prophylactic treatment by administering an effective amount of at least one of these carboxamide compounds.The carboxamide compounds are compounds of the general formula Iin whichW—R2 is selected fromand R1, R2, R3a, R3b, Y1, Y2, Y3, Y4, X, Q, m, k, Rw and Rw* have the meanings mentioned in the claims, the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y1, Y2, Y3 and Y4 are CRy, or one or two of the variables Y1 to Y4 are a nitrogen atom and the remaining variables are CRy, wherein the radicals Ry may be identical or different and have the meanings mentionend in the claims.
Owner:ABBVIE DEUTSHLAND GMBH & CO KG +1

C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

This invention is directed to novel oxamyl dipeptide ICE / ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.
Owner:CONATUS PHARMA

Activity-based probes and methods of their preparation ans use

The present invention provides compositions and methods for assessing profiles of catalytically active enzymes in compositions containing a plurality of proteins. In preferred embodiments, the enzyme is a hydrolase, most preferably a cysteine protease. The methods described herein use activity based probes (“ABPs”) that have an affinity moiety for directing the binding of the ABP to one or more catalytically active target enzymes, a reactive group for forming a covalent bond at an active site of the target enzyme(s), and a TAG (e.g., a detectable label, preferably a fluorophore). One or more ABPs may be combined with a protein-containing sample under conditions for binding and reaction of the ABP(s) with target enzyme(s) that are present in the sample. The resulting products may then be used to assess the active enzyme profile of the sample, and can be correlated to the presence, amount, or activity of one or more target enzyme(s) present in the original complex protein mixture.
Owner:FROG +6

Triazine compound or pharmaceutically acceptable salt, isomer, pharmaceutical composition and application thereof

The invention discloses a triazine compound with a structure as shown in a general formula I or pharmaceutically acceptable salt, isomer, metabolite, prodrug, solvate or hydrate, pharmaceutical composition and application thereof. The triazine compound provided by the invention overcomes the defects of single structure, lack of non-covalent high-efficiency small-molecule inhibitors and the like of the existing anti-coronavirus drugs, has good inhibitory activity on 3C-like cysteine protease, has excellent pharmacokinetic properties, and has a good treatment effect on infectious diseases.
Owner:YAOKANG ZHONGTUO (JIANGSU) PHARMA TECH CO LTD

Propenoyl hydrazides

The present disclosure provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure include a peptidyl propenoyl hydrazide compositions that inhibit proteases, for example cysteine proteases, either in vivo or in vitro.
Owner:GEORGIA TECH RES CORP

Engineered bombyx mori baculovirus vector and method of increasing the NS1 expression amount by utilization of the vector

InactiveCN104017826AHigh expressionProduction of quick decisionsGenetic engineeringFermentationProtein targetChitinase
The invention discloses an engineered bombyx mori baculovirus vector. The vector is obtained by replacing chitinase and cysteine protease genes in a bombyx mori baculovirus vector Bm-Bacmid with a Cm expression cassette and an egfp expression cassette which are in series connection. The egfp gene in the engineered vector is subjected to integrated expression, and can be used for monitoring cell transfection or infection and conditions after insects are infected in real time. By utilization of the vector, a bombyx mori bidensovirus nsl gene expression cassette is inserted into a transposition site, and a BmN cell or bombyx mori is infected by the prepared recombinant virus, so that expression of a targeting gene can be obtained. Results show that: the vector lacks Chitinase and Cystein Protease genes, delays cell lysis and insect liquidation, facilitates expression of an exogenous gene and inhibits digestion of a targeting protein to a certain degree, thus increasing the expression amount of the nsl gene and laying sound foundations for deep research of the structure and functions of the NS1 protein.
Owner:JIANGSU UNIV

Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R1, R2, R3, R4, R5, R6, R8, R9 and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds
Owner:BOEHRINGER INGELHEIM PHARMA INC

Method and Pharmaceutical Composition for Treating Psoriasis, Squamous Cell Carcinoma and/or Parakeratosis by Inhibiting Expression of Squamous Cell Carcinoma-Related Antigen

In a first aspect thereof, the present invention provides a method for treatment and / or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a method for screening for substances that inhibit epidermal parakeratosis, wherein the activity of a candidate substance that inhibits cysteine protease inhibitory activity possessed by squamous cell carcinoma antigen 1 (SCCA-1) is used as an indicator.
Owner:SHISEIDO CO LTD

Compounds useful as reversible inhibitors of cysteine proteases

Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds
Owner:BOEHRINGER INGELHEIM PHARMA INC

Pear lignin synthesis gene PbMC1a/1b and application of pear lignin synthesis gene PbMC1a/1b in genetic improvement of fruit quality

The invention discloses a pear lignin synthesis gene PbMC1a / 1b and application of the pear lignin synthesis gene PbMC1a / 1b in genetic improvement of fruit quality. The PbMC1a / 1b gene is a cysteine-like protease isolated and cloned from Dangshansu pear with high lignin content, an applicant names the gene as PbMC1a / 1b, the sequence is shown as SEQ ID NO.1, and the corresponding amino acid sequenceis shown as SEQ ID NO.2. A gene construction over-expression vector is introduced into arabidopsis thaliana, obtained transgenic plants are verified by a biological function, the cloned PbMC1a / 1b genecan promote the cell walls of fibers between ducts, lignocellulosic fibers and vascular bundles to be obviously thickened, lignin accumulation in stems is promoted and plant growth is inhibited, theexpression of genes related to lignin biosynthesis is increased, new genetic resources is provided for molecular design and breeding of fruit quality, and the PbMC1a / 1b gene is an important candidategene for future genetic engineering to improve fruit quality breeding.
Owner:NANJING AGRICULTURAL UNIVERSITY

Methods for the synthesis of alpha- hydroxy-beta-amino acid and amide derivatives

Methods for the synthesis of alpha-hydroxy-beta-amino acid and amide derivatives and alpha-ketoamide derivatives and novel derivatives made by these methods are provided. These methods involve reacting a N-terminally blocked (protected) aminoaldehyde with an isonitrile and a carboxylic acid to give an amino-alpha-acyloxy carboxamide. The acyloxy group may be removed to give the derivative. Alternatively the protecting group is removed and acyl shift occurs to give the derivative. These derivatives are useful in the synthesis of compounds such as peptidyl alpha-ketoamides and alpha-hydroxy-beta-carboxylic acid and amide derivatives. Certain of these compounds have been reported to have activity as inhibitors of proteases, such as serine proteases and cysteine proteases.
Owner:CORVAS INT INC

Cysteine protease inhibitors

InactiveUS20090291945A1Excellent cysteine protease inhibitory effectBiocideOrganic chemistryPAGET'S BONE DISEASECysteine Proteinase Inhibitors
To provide a compound having an excellent cysteine protease inhibitory effect, and to provide a drug for treatment or prevention of the disease selected from the group consisting of osteoporosis, osteoarthritis, chronic rheumatoid arthritis, Paget's disease of bone, hypercalcemia, bone metastasis of cancer, and ostealgia. A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, or a drug or pharmaceutical composition containing the same as an effective component.
Owner:TEIJIN PHARMA CO LTD

Nucleotide sequence for assessing transmissible spongiform encephalopathies

The present invention is directed to the assessment of transmissible spongiform encephalopathy (TSE) using a sample from a living individual. The assessment is based on the use of an RNA marker molecule in a sample of whole blood. The RNA encodes a hypothetical cystein protease. The invention is further directed to the detection of the marker molecule by means of real-time PCR. The invention provides the use of the nucleotide sequence as a marker in the assessment of TSE, a method for assessing bovine spongiform encephalopathy (BSE) in a bovine animal as well as kits to practice the invention.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC

Peanut cysteine protease encoding gene AhRD21A as well as expression vector and application thereof

The invention discloses a peanut cysteine protease encoding gene AhRD21A, the construction of an overexpression vector of the peanut cysteine protease encoding gene AhRD21A and the application of the peanut cysteine protease encoding gene AhRD21A in tobacco bacterial wilt resistance genetic engineering. The gene contains a nucleotide sequence as shown in SEQ ID No. 1. The CaMV 35S promoter-driven overexpression vector agrobacterium-mediated transformation bacterial wilt susceptible variety Honghua Dajinyuan is constructed through a Gateway system, molecular detection and ralstonia solanacearum inoculation recognition are carried out on transgenic plants, and overexpression of the CaMV 35S promoter-driven overexpression vector agrobacterium-mediated transformation bacterial wilt susceptible variety Honghua Dajinyua in tobaccos can significantly improve bacterial wilt resistance of transgenic tobaccos. The result shows that the AhRD21A may participate in the resistance reaction of the plant to the bacterial wilt, which has an important gene resource for the bacterial wilt resistance genetic engineering breeding application of the plant.
Owner:FUJIAN AGRI & FORESTRY UNIV

Cysteine protease inhibitors

of the formula (IV): where: R1=R'C(O), R'SO2, R'=a bicyclic, saturated or unsaturated, 8-12 membered ring system containing 0-4 hetero atoms selected from S, O and N, which is optionally substituted with up to four substituents independently selected from groups a), b) and c) below; or R'=a monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3 hetero atoms selected from S, O and N, which monocyclic ring bears at least one substituent selected from group a) and / or c) and which may optionally bear one or two further substituents selected from group b); R4=H, C1-7-alkyl, Ar-C1-7-alkyl, Ar, C3-7-cycloalkyl; C2-7alkenyl; R3=C1-7-alkyl, C2-C7 alkenyl, C2-C7 alkenyl, C3-7-cycloalkyl, Ar-C1-7-alkyl, Ar; R5=C1-7-alkyl, halogen, Ar-C1-7-alkyl, C1-3-alkyl-CONR3R4 or a bulky amine R6 is H, C1-7-alkyl, Ar-C1-7-alkyl, C1-3-alkyl-SO2-R<ix>, C1-3-alkyl-C(O)-NHR<ix >or CH2XAr q is 0 or 1 have utility as inhibitors of cysteine proteases such as cathepsin K and falcipain.
Owner:MEDIVIR AB

Triazine compound as well as preparation method and application thereof

The invention discloses a triazine compound with a structure as shown in a general formula I or pharmaceutically acceptable salt, isomer, metabolite, prodrug, solvate or hydrate, pharmaceutical composition and application thereof. The compound disclosed by the invention overcomes the defects of single structure, lack of non-covalent and non-peptide high-efficiency small-molecule inhibitors and the like of the existing broad-spectrum antiviral drugs, and the compound disclosed by the invention has very good inhibitory activity on 3C-like cysteine protease and has a good treatment effect on infectious diseases.
Owner:YAOKANG ZHONGTUO (JIANGSU) PHARMA TECH CO LTD

Silinane compounds as cysteine protease inhibitors

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.
Owner:SCHERING AG

Peptidomimetic compound as well as derivative, preparation method, pharmaceutical composition and application thereof

The invention discloses a peptidomimetic compound and a derivative thereof, the chemical structural formula of the compound is as shown in formula (I), and the derivative is a tautomer, a stereoisomer, a solvate, a salt of the solvate, a metabolite, a metabolic precursor or a prodrug, a pharmaceutically acceptable salt or a mixture of the tautomer, the stereoisomer, the solvate, the salt of the solvate, the metabolite, the metabolic precursor or the prodrug and the pharmaceutically acceptable salt of the compound. The peptidomimetic compound and the derivative of the peptidomimetic compound can effectively inhibit 3C-like cysteine protease, and can be prepared into drugs for treating and / or preventing SARS-CoV, HBV, HCV, H1N1, Ebola or SARS-CoV-2 virus infection diseases.
Owner:YAOKANG ZHONGTUO (JIANGSU) PHARMA TECH CO LTD

Nitriles useful as reversible inhibitors of cysteine proteases

Disclosed are novel nitrile compounds of formula (I) further defined herein, which compounds are useful as reversible inhibitors of cysteine proteases such as cathepsin K, S, F, L and B. These compounds are useful for treating diseases and pathological conditions exacerbated by these proteases such as, but not limited to, osteoporosis, rheumatoid arthritis, multiple sclerosis, asthma and other autoimmune diseases, Alzheimer's disease, atherosclerosis. Also disclosed are processes for making such novel compounds.
Owner:BOEHRINGER INGELHEIM PHARMA INC

Heat-resistant cysteine protease, and coding genes and applications thereof

The invention discloses a heat-resistant cysteine protease, and coding genes and applications thereof. The heat-resistant cysteine protease is a protein selected from proteins: a, composed of amino acid sequences represented by SEQ ID NO.1; b, which possess protein degradation activity under high temperature conditions and are obtained via substitution and / or deletion and / or inserting of one or aplurality of amino acid residues of amino acid sequences represented by SEQ ID NO.1. The invention also discloses applications of the heat-resistant cysteine protease in degrading proteins under hightemperature conditions. The heat-resistant cysteine protease possesses high efficiency protein degrading activity as a temperature as high as 75 DEG C, and the high efficiency catalytic activity may last for 30min or longer in a solution of a temperature as high as 85 DEG C.
Owner:TECHNICAL INST OF PHYSICS & CHEMISTRY - CHINESE ACAD OF SCI

Crystal structure of house dust mite allergen Der p 1

The present invention relates to a crystal structure of house dust mite allergen proDer p 1, the three-dimensional structure of proDer p 1 and the use of the three-dimensional structure to design a mutant of a protein belonging to the papain-like cysteine proteases.
Owner:ALK ABELLO SA

Bone-strengthening probiotic formula milk powder for preventing senile osteoporosis

PendingCN114403235AImprove and strengthen densityReduce incidenceWhey manufacturePhospholipidSodium hyaluronate
The invention discloses bone-strengthening probiotic formula milk powder for preventing senile osteoporosis, and every 100 g of the formula milk powder comprises the following components: desalted whey powder, inulin, calcium carbonate, 3.8-6.2 g of fructo-oligosaccharide, xylooligosaccharide, vitamin A (retinyl acetate), vitamin D (cholecalciferol), vitamin E (dl-alpha-tocopheryl acetate), ferrous sulfate, sodium selenite and the balance of water. The milk powder is prepared from the following raw materials by weight: 5g of yak bone marrow collagen peptide powder, 0.4-0.6 g of phospholipid, L-carnitine, sodium hyaluronate, milk mineral salt, hydrolyzed yolk powder, bifidobacterium lactis HN019 and the balance of skim milk powder. On the basis of the prior art, in addition to reasonable matching of calcium, phosphorus and vitamins, probiotics, angiopoietin and cysteine-inhibiting protease protein are particularly added, the bone tissue density is further improved and strengthened, and therefore the occurrence rate of osteoporosis is more effectively reduced.
Owner:成都桥然生物科技有限公司

Haloalkyl Containing Compounds as Cysteine Protease Inhibitors

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC

Di-fluoro containing compounds as cysteine protease inhibitors

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Owner:VIROBAY INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products